Literature DB >> 7578125

Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase.

A Mazumder1, A Gazit, A Levitzki, M Nicklaus, J Yung, G Kohlhagen, Y Pommier.   

Abstract

Efficient replication of HIV-1 requires establishment of the proviral state, i.e., the integration of a DNA copy of the viral genome, synthesized by reverse transcriptase, into a chromosome of the host cell. Integration is catalyzed by the viral integrase protein. We have previously reported that phenolic moieties in compounds such as napthoquinones, flavones, caffeic acid phenethyl ester (CAPE), and curcumin confer inhibitory activity against HIV-1 integrase. We have extended these findings by examining the effects of tryphostins, tyrosine kinase inhibitors. The catalytic activities of HIV-1 integrase and the formation of enzyme-DNA complexes using photocross-linking were examined. Both steps of the integration reaction, 3'-processing and strand transfer, were inhibited by tyrphostins at micromolar concentrations. The DNA binding activity of integrase was inhibited at higher concentrations of tryphostins. Disintegration, an apparent reversal of the strand transfer reaction, catalyzed by an integrase mutant lacking the N-terminal zinc finger and C-terminal DNA binding domains is also inhibited by tyrphostins, indicating that the binding site for these compounds resides in the central catalytic core of HIV-1 integrase. Binding of tyrphostins at or near the integrase catalytic site was also suggested by experiments showing a global inhibition of the choice of attacking nucleophile in the 3'-processing reaction. None of the tryphostins tested inhibited eukaryotic topoisomerase I, even at 100 microM, suggesting selectivity for integrase inhibition. Molecular-modeling studies have revealed that, after energy minimization, several tyrphostins may adopt folded conformations. The similarity of the tyrphostin family to other families of inhibitors is discussed. Tyrphostins may provide lead compounds for development of novel antiviral agents for the treatment of acquired immunodeficiency syndrome based upon inhibition of HIV-1 integrase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578125     DOI: 10.1021/bi00046a018

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.

Authors:  C M Farnet; B Wang; J R Lipford; F D Bushman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

2.  Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase.

Authors:  P J King; W E Robinson
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism.

Authors:  C M Farnet; B Wang; M Hansen; J R Lipford; L Zalkow; W E Robinson; J Siegel; F Bushman
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Equivalent inhibition of half-site and full-site retroviral strand transfer reactions by structurally diverse compounds.

Authors:  D Hazuda; P Felock; J Hastings; B Pramanik; A Wolfe; G Goodarzi; A Vora; K Brackmann; D Grandgenett
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors.

Authors:  N Neamati; A Mazumder; H Zhao; S Sunder; T R Burke; R J Schultz; Y Pommier
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Differential divalent cation requirements uncouple the assembly and catalytic reactions of human immunodeficiency virus type 1 integrase.

Authors:  D J Hazuda; P J Felock; J C Hastings; B Pramanik; A L Wolfe
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

7.  Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA).

Authors:  Devendra K Dhaked; Jitender Verma; Anil Saran; Evans C Coutinho
Journal:  J Mol Model       Date:  2008-12-02       Impact factor: 1.810

8.  Inhibiting the HIV integration process: past, present, and the future.

Authors:  Roberto Di Santo
Journal:  J Med Chem       Date:  2013-09-25       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.